KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Liabilities and Shareholders Equity: 2009-2025

Historic Liabilities and Shareholders Equity for Arbutus Biopharma (ABUS) over the last 15 years, with Sep 2025 value amounting to $97.7 million.

  • Arbutus Biopharma's Liabilities and Shareholders Equity fell 30.43% to $97.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $449.7 million, marking a year-over-year decrease of 24.44%. This contributed to the annual value of $131.7 million for FY2024, which is 8.79% down from last year.
  • According to the latest figures from Q3 2025, Arbutus Biopharma's Liabilities and Shareholders Equity is $97.7 million, which was down 5.38% from $103.3 million recorded in Q2 2025.
  • Arbutus Biopharma's 5-year Liabilities and Shareholders Equity high stood at $236.9 million for Q1 2022, and its period low was $97.7 million during Q3 2025.
  • Its 3-year average for Liabilities and Shareholders Equity is $142.9 million, with a median of $144.4 million in 2023.
  • Per our database at Business Quant, Arbutus Biopharma's Liabilities and Shareholders Equity soared by 61.98% in 2022 and then plummeted by 35.48% in 2025.
  • Arbutus Biopharma's Liabilities and Shareholders Equity (Quarterly) stood at $204.5 million in 2021, then decreased by 4.43% to $195.4 million in 2022, then declined by 26.11% to $144.4 million in 2023, then declined by 8.79% to $131.7 million in 2024, then tumbled by 30.43% to $97.7 million in 2025.
  • Its last three reported values are $97.7 million in Q3 2025, $103.3 million for Q2 2025, and $117.0 million during Q1 2025.